These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36836029)

  • 21. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
    Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis.
    Kim YI
    Nucl Med Commun; 2021 Apr; 42(4):451-458. PubMed ID: 33346603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 24. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
    Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
    Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
    Strosberg J; Leeuwenkamp O; Siddiqui MK
    Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
    Bodei L; Cremonesi M; Ferrari M; Pacifici M; Grana CM; Bartolomei M; Baio SM; Sansovini M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1847-56. PubMed ID: 18427807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review.
    Kashyap R; Raja S; Adusumilli A; Gopireddy MMR; Loveday BPT; Alipour R; Kong G
    J Neuroendocrinol; 2024 Jun; ():e13425. PubMed ID: 38937270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.
    Sierra ML; Agazzi A; Bodei L; Pacifici M; Aricò D; De Cicco C; Quarna J; Sansovini M; De Simone M; Paganelli G
    Cancer Biother Radiopharm; 2009 Dec; 24(6):659-65. PubMed ID: 20025545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
    Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
    Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Bal C
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1595-1606. PubMed ID: 34837103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis.
    Dannoon SF; Alenezi SA; Elgazzar AH
    Nucl Med Commun; 2017 Dec; 38(12):1085-1093. PubMed ID: 28957840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma.
    Jaiswal SK; Sarathi V; Memon SS; Garg R; Malhotra G; Verma P; Shah R; Sehemby MK; Patil VA; Jadhav S; Lila AR; Shah NS; Bandgar TR
    Endocr Connect; 2020 Oct; 9(9):864-873. PubMed ID: 32784267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis.
    Su D; Yang H; Qiu C; Chen Y
    Front Oncol; 2023; 13():1141648. PubMed ID: 37483516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Sabet A; Nagarajah J; Dogan AS; Biersack HJ; Sabet A; Guhlke S; Ezziddin S
    EJNMMI Res; 2013 Dec; 3(1):82. PubMed ID: 24369053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer.
    Kasi PM; Sharma A; Jain MK
    Case Rep Oncol; 2019; 12(1):98-103. PubMed ID: 31043945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE.
    Pettersson OJ; Fröss-Baron K; Crona J; Sundin A
    Endocr Connect; 2021 Apr; 10(4):422-431. PubMed ID: 33875614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
    Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.